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Objective. Highlighting the apelin system would present a new therapeutic target for liver disease. Apelin; endogenous ligand for
the orphan receptor APJ, was recently suggested to be associated with ﬁbrosis progression and cirrhosis in addition to insulin
resistance (IR) and inﬂammation. The present study was conducted to evaluate blood apelin level changes among 73 chronic
hepatitis C (CHC) Egyptian patients and if associated with body mass index (BMI), IR, and tumor necrosis factor-alpha (TNF-
α). Serum apelin levels were signiﬁcantly higher in patients with CHC with median value (3.25) when compared with controls
(1.11), at P<0.0001, with signiﬁcant apelin variations among asymptomatic carriers (ASC), ﬁbrosis, and cirrhosis patients, and
also among obese and nonobese patients. Multiple regression analysis depicted that BMI, triglycerides, and total cholesterol were
independent correlation factors to apelin levels, whereas TNF-α was found to be signiﬁcantly negatively correlated to adjusted
apelin in CHC patients (r =− 0.5944, P<0.0001). IR was positively correlated to adjusted apelin in CHC patients (r = 0.2663,
P<0.05).Conclusion. Apelin level varies amongstages of CHC, which may contribute to ﬁbrosis progression.In addition, obesity
and IR could act as comorbid factors aﬀecting apelin level in patients with CHC.
1.Introduction
The receptor APJ remained orphan until 1998, when Tate-
moto and his coworkers isolated its endogenous ligand from
bovine stomach extract. They isolated a 36-amino-acid pep-
tide which was named apelin (from APJ endogenous ligand)
[1]. Apelin exists in at least three forms, consisting of 13, 17,
or36amino acids,alloriginating fromacommon77-amino-
acid precursor [2]. Apelin has been shown to be involved
in vessel formation, where it exerts a pro-angiogenic role
[3, 4], and in the regulation of cardiovascular function, by
reducing arterial blood pressure, via stimulation of nitric
oxide-mediated vasorelaxation [5, 6]. Moreover, apelin has
recently been added to the family of adipokines [7, 8], which
areadipocytokinesmainlyderivedfromadiposetissueaswell
as endothelial cells (ECs) in various parts of the body [2].
H e p a t i t i sCv i r u s( H C V )h a sb e e nr e c o g n i z e da sam a j o r
cause of chronic liver disease(s) (CLD) in Egypt [9]. The
emerging role of apelin in CLD is complex, as described in a
recentreportlinkingapelintotheinitiationandmaintenance
of the inﬂammatory and ﬁbrogenic processes occurring in
theﬁbroticliver[10],as well as tothevascular andhaemody-
namic abnormalities in cirrhosis and its complications [11,
12]. However, clinical data demonstrating the role of apelin
in CLD is limited, as depicted by Bertolani and Marra [13].
Althoughbarelydetectableinnormal liver,productionof
TNF-α from T-cells occurs at the early onset in many types
of liver injury and has been related to ﬁbrosis progression
[14]. Moreover, adipokines as leptin, resistin, visfatin, and
adiponectin are recently considered as regulators of liver
ﬁbrogenesis and may explain why obesity inﬂuences ﬁbrosis
progression [15].
Hepatic insulin signaling is markedly impaired in HCV
p a t i e n t s ;i na d d i t i o n ,d o w nr e g u l a t i o no fh e p a t i ci n s u l i nm e -
diators is associated with enhanced hepatocyte apoptosis
and ﬁbrogenesis [16]. Currently some evidence supports a
relationship between insulin resistance (IR) and hepatitis C
on one hand, playing role in progression of liver disease [17–
20], and between IR and apelin level on the other hand in
cases of obesity [7].2 Mediators of Inﬂammation
Therefore,highlightingtheapelinsystemwouldpresenta
new therapeutictarget for liver disease. Thus, this study aims
to address if there is relation between apelin serum levels
and liver disease progression in a previously characterized
cohort of established CHC Egyptian patients. The second
question is whether obesity, inﬂammation (TNF-α), and IR
are cofounders for this association.
2.Subjectsand Methods
2.1. Subjects. The studied groups included (85) subjects.
Twelve subjects served as healthy controls (group I) selected
from healthy subjects working in, or attending with their
relatives, to the outpatient clinics of Ain Shams University
Specialized Hospitals(ASUSH).Noneofthe healthy controls
took any medication or dietary supplements including vita-
min(s) and/or antioxidant(s).
Seventy three patients with CHC were selected from
Cairo Liver Center, Dokki, Cairo, Egypt. After protocol ap-
proval, the study was conducted in the period from Decem-
ber 2009 to December 2010. All subjects gave written in-
formed consent prior to participation and the study was
approved by the Committees on Medical Ethics of the Cairo
LiverCenterandASUSH.Thestudywascarried outinaccor-
dance with the regulations and recommendations of the
Declaration of Helsinki.
Patients enrolled in the study were classiﬁed into the fol-
lowing groups: asymptomatic chronic hepatitis C carriers
(ASC) (group II) (n = 20) with normal liver function tests
(LFTs), namely, alanine transaminase; ALT, for at least 6
months. Group III were patients with liver ﬁbrosis (n = 20)
and patients with cirrhosis (group IV) (n = 33). Histopath-
ological staging was done using METAVIR scoring system
where ﬁbrosis was staged as (F1–F3) and (F4) represents
established cirrhosis [21]. Cirrhosis was previously diag-
nosed by evidence Stigmata, lab, and radiographic proce-
dures. Steatosis was assessed by liver biopsy and features de-
tected by ultrasound.
The following exclusion criteria were used for all sub-
jects: hypertension, cardiopulmonary disease, renal disease,
endocrine disorders including diabetes, malignancy, having
previous interferon treatment or recently received any anti-
inﬂammatory drugs, as well as smokers and alcoholics, and
othercausesofCLDaschronichepatitisB,autoimmunehep-
atitis, acute hepatitis, haemochromatosis, hepatocellular car-
cinoma, and biliary disorders. Additional criteria for chronic
hepatitis patients include age at diagnosis ≥40 years.
2.2. Methods
2.2.1. Data Collection. A detailed drug treatment(s) history
was collected, and physical examination of the patients was
carried out with special emphasis on previous surgical pro-
cedures and prior parenteral therapy. Complete clinical ex-
amination was done, on the day of sample withdrawal which
included the manifestations of hepatitis such as hepatomeg-
aly, tenderness in the right hypochondrium, splenomegaly,
and lower limb edema, or liver cell failure such as jaundice,
hepatic encephalopathy, bleeding varices, and ascites. Biopsy
samples were assessed unless contraindication or estab-
lished cirrhosis was present; abdominal ultrasonography and
endoscopy were also done side by side with routine labora-
tory investigations including complete blood picture, liver,
and kidney function tests. HCV was diagnosed by anti-HCV
assay by a third generation enzyme immunoassay, and HCV
RNA by real time PCR. Medical records indicated that all
patients were of HCV genotype 4 which is the most common
in Egyptian patients.
Body mass index (BMI) was calculated as an index of the
weight (in kilograms) divided by the square of the height (in
meters) measured on the same day of sample withdrawal.
Centers for Disease Control and Prevention (CDC) classify
the normal range of BMI to be between 18.5–24.9kg/m2,
overweight BMI between 25–29.9kg/m2,a n dt h eo b e s e
BMI > 30kg/m2 [22]. Since BMI could be inﬂuenced by the
presence of ascites in patients with cirrhosis, earlier weights
takenpriortothediagnosis ofasciteswere usedforthecalcu-
lation of BMI [23].
2.2.2. Sample Preparation, Collection, and Storage. All sub-
jects were advised to take no medication on the morning
before blood sample collection. Fasting blood (5mL) was
obtained from the antecubital vein, after an overnight
fasting period (10–12 hours). Samples were divided into two
parts; one containing trisodium citrate (ﬁnal concentration
1mg/mL) for prothrombin time (PT) determination. The
otherpart was takeninto vacutainerclottedtubes,wheresera
were separated by centrifugation at 3000rpm for 10min for
otherlabmeasurements. Otherseraaliquotswerekeptfrozen
at −70◦Cformeasurement ofserumapelin(withnoneedfor
aprotinin pretreatment stepapplied toplasma samples [24]),
TNF-α, and insulin.
2.2.3. Laboratory Assessments. Sera were obtained, aliquoted
for the measurement of LFTs: aspartate transaminase (AST),
ALT, bilirubin, albumin, fasting blood glucose (FBG), and
lipids (total cholesterol (TC) and triacylglycerol (TAG))
by using standard enzymatic techniques using appropriate
kits and semiautomated photometer 5010. Determination of
serum apelin (Phoenix Pharmaceuticals, Burlingame, Calif)
using the apelin-12 microplate enzyme-linked immunosor-
bant assay (ELISA) kit, TNF-α (Orgenium laboratories
ELISA), and insulin (Monobind Inc.) using enzyme-linked
immunosorbant assay (ELISA) kits, and, following ELISA,
procedures were carried out according to the manufacturers’
instructions.
Insulin resistance was determined by the homeostasis
model of assessment (HOMA) [25] using the formula: fast-
ing insulin (μIU/mL) × fasting blood glucose (mg/dL)/405.
2.3. Statistical Analysis. SPSS statistics (V. 19.0, IBM Corp.,
USA, 2010) was used for data analysis. Data was expressed
as mean ± S.D for quantitative parametric measures, in
addition to median and IQR for nonparametric data and
percentiles for categorical data. Student’s t test was used for
comparison of two independent groups for parametric dataMediators of Inﬂammation 3
Table 1: Demographic, clinical characteristics, and studied parameters of all participants.
Groups/parameters Control Liver disease P
n 12 73
Age (years) 51 ± 3.7 52.4 ± 5.8 NS
Gender (M/F) Φ 6/6 48/25 NS
BMI (Kg/m2)2 3 ± 1.6 28.7 ± 5.2
BMI (18.5–24.9), lean n (%) 12 (100%) 37 (51%)
BMI (30–35), obese n (%) 0 36 (49%)
ASC/ﬁbrosis/cirrhosis — 20/20/33
Fatty liver — 14 (19%)
Portal hypertension∗ and/or ascites — 20 (27%)
HOMA-IR§ 1.85 (1.63–2) 3.28 (2.3–4.7) 0.001
IR n (%) — 43 (59%)
TNF-α (pg/mL)§ 76.6 (43–141) 297.0 (205.5– 457.2) <0.0001
Apelin (ng/mL)§ 1.11 (0.83–1.42) 3.25 (2.6–3.9) <0.0001
Data are mean ± S.D, Φ-male to female ratio, § = median (25th and 75th centiles-quartiles). ∗surrogate markers of portal hypertension, esophageal varices,
splenomegaly, and thrombocytopenia.
Table 2: Serum concentrations of the studied parameters in the diﬀerent studied groups.
Groups, n/Parameter Control, 12
Liver diseases, 73
P1 P2 P3
ASC, 20 Fibrosis, 20 Cirrhosis, 33
AST (U/L) 23.6 ± 23 6 ± 7.5 70 ± 10 69 ± 20 NS <0.0001 <0.0001
ALT§ (U/L) 26 (23–28) 37.5 (28–50) 100 (40–140) 43 (34–60) NS 0.015 NS
Bilirubin § (mg/dL) 0.7 (0.6–0.7) 0.75 (0.6–1) 0.9 (0.7–1.1) 2.2 (1.2–2.95) NS <0.0001 0.001
Albumin (gm/dL) 3.86 ± 0.27 4 ± 0.22 3.9 ± 0.32 2.8 ± 0.6 NS 0.009 <0.0001
PT % 85 ± 7.3 81 ± 7.3 73.3 ± 6.8 52 ± 13.4 0.019 <0.0001 <0.0001
Glucose (mg/dL) 82 ± 8.7 98 ± 8.5 87 ± 10.7 88 ± 10.7 0.001 NS 0.01
TC (mg/dL) 167 ± 21 176 ± 11.6 177.5 ± 16.2 182 ± 16 NS NS NS
TAG (mg/dL) 100 ± 21 123 ± 37 134 ± 33 122 ± 25 NS NS NS
HOMA-IR§ 1.85 (1.63–2) 2.75 (1.9–3.6)a 4.26 (2.4–5.8)a 4.1 (2.42–7.7)a NS NS 0.015
IR n (%) 0 8 (40%) 12 (60%) 23 (70%)
TNF-α (pg/mL)§ 76.6 (43–141) 616 (535–694)a 205 (157–267)a 280 (205–337)a 0.014 0.002 0.004
Apelin (ng/mL)§ 1.11 (0.83–1.42) 2 (1–2.54)a 3 (2.9–3.3)a 3.9 (3.6–4)a 0.001 <0.0001 <0.0001
Apelin-adj (ng/mL)§ 0.8 (0.3–1) 0.52 (0.16–0.93) 1.77 (1.17–2)a 2.3 (1.9–2.6)a 0.005 <0.0001 <0.0001
Data are mean ± S.D, § = median (25th and 75th centiles-quartiles). asigniﬁcant diﬀerence from healthy controls at P ≤ 0.05. AST: Aspartate transaminase;
ALT: Alanine Transaminase; PT: Prothrombin time; TC: total cholesterol; TAG: triacylglycerols. P1 for comparison of ASC and ﬁbrosis groups, P2f o r
comparison of ﬁbrosis and cirrhosis groups, and P3 for comparison of ASC and cirrhosis groups.
and Wilcoxon Rank Sum for nonparametric data. However,
for comparison between more than 2 patient groups for pa-
rametric data, we used analysis of variance (ANOVA).Multi-
ple comparisons (Post hoc test: LSD (least signiﬁcant diﬀer-
ence))were alsofollowed toinvestigatethepossiblestatistical
signiﬁcance between each 2 groups. Moreover, comparison
between more than 2 patients’ groups for nonparametric
dataKruskallWallistestwasused.Finally,Spearman’sranked
correlation test, to study the possible association between
each two variables among each group for nonparametric
data, using the probability of error at 0.05 was considered
signiﬁcant, while at 0.01 and 0.001 were highly signiﬁcant.
Multiple linear regression analysis was done on all measured
parameters to allow for adjustment of apelin level.
3.Results
No signiﬁcant diﬀerences with regards to age or gender dis-
tribution existed among groups. The clinical and demo-
graphiccharacteristics as well as studiedparameters ofall pa-
rticipants (control and CHC patients) are shown in Table 1.
Signiﬁcant diﬀerences in median values of apelin, TNF-
α, and HOMA-IR levels existed between control and CHC
patients as shown in Table 1.
CHC patients were subdivided into three groups: ASC
(20 patients), ﬁbrotic (20 patients), and cirrhotic (33 pa-
tients). Laboratory investigations and studied parameters for
each group are detailed in Table 2. Regarding IR, it was
signiﬁcantly higher in all groups when compared to control.4 Mediators of Inﬂammation
It was also signiﬁcantly higher in cirrhotic patients (4.1) in
comparison to ASC (2.75). TNF-α level was also higher in all
groups in comparison to controls with median (76.6) being
highest among ASC (616).
HCV-related disease progression was associated with
greater median values of apelin compared to nondiseased
control patients, while those with cirrhosis had the highest
apelin concentrations among those with liver disease, with
median value (3.9). Patients with ﬁbrosis also displayed
higher median values of apelin (3) when compared to either
controls (1.11) or ASC (2), with nonsigniﬁcant diﬀerences
among diﬀerent ﬁbrosis Metavir scores. These results were
consistent when apelin was adjusted for BMI, TAG, and TC
covariants, whereas elevation in apelin levels disappeared
only in case of ASC after adjustment as depicted in Table 2.
Table 3 illustrates apelin levels among diﬀerent 2 patient
subgroups, where cirrhotic patients (n = 33) were further
subdivided into: (a) patients not suﬀering from complica-
tions including portal hypertension and/or ascites (13 sub-
jects); (b) patients encountering complications as portal hy-
pertension and/or ascites (20 patients). Upon comparing
adjusted-apelin level among the two subgroups, it was found
to be signiﬁcantly higher in those with complications with
median (2.36) in comparison to those free of such complica-
tions (1.87) as shown in (Table 3).
In an attempt to test our second aim reclaiming whether
obesityisacofounderforapelinserumlevelsassociationwith
CHC disease progression, we analyzed apelin levels in the
obese (36 patients) versus lean (37 patients). It was found to
be signiﬁcantly higher in the latter with median value (3.6)
versus (2.96) in the former (Table 4).
Additionally, CHC patients were subdivided into IR (43
patients)and non-IR (30patients).Adjusted-apelin levelwas
signiﬁcantly higher in IR subjects with median (1.9) than
non-IR ones (1.7) (Table 4).
Correlations of adjusted-apelin levelsto diﬀerentparam-
eters showed modest positive relation to IR in all CHC
patients (r = 0.2663, P<0.05) (Figure 1(a)). Such relation
appeared to be signiﬁcant in group of ASC (r = 0.665,
P<0.01) but was nonsigniﬁcant for ﬁbrotic and cirrhotic
groups (Table 5).
Additionally, adjusted-apelin was found to be negatively
correlated to TNF-α in all CHC patients (n = 73) with
high signiﬁcance (r =− 0.5994, P<0.0001) (Figure 1(b)).
Further analysis within patients groups revealed signiﬁcant
negative correlation in the cirrhotic group (r =− 0.488,
P<0.01) (Table 5). However, it was nonsigniﬁcant for both
ASC and ﬁbrotic groups.
4.Discussion
Recent emerging studies pointed to the possible multiple
eﬀects of the apelinergic system in the liver and related it to
oxidativestress, inﬂammation [8],ﬁbrosis [10],angiogenesis
[26], as well as haemodynamic and vascular disturbances
[11, 12].
Apelin was evaluated in all groups both before and after
adjustment for BMI, TAG, and TC that acted as potential
Table 3: Adjusted-apelin levels among cirrhotic patients group
(n = 33).
Cirrhotic patients group n Adjusted-apelin
(ng/mL)
Free of complications 13 1.87 (1.33–2.4)
With complications 20 2.36 (1.55–2.6)a
Data are medians (25th and 75th centiles-quartiles). asigniﬁcant diﬀerence
fromcirrhoticpatientsfreeofcomplications(PHand/orascites)atP ≤ 0.05.
Table 4: Apelin and adjusted-apelin levels among diﬀerent CHC
groups (n = 73).
n Apelin (ng/mL) Adjusted-apelin
(ng/mL)
Lean patients 37 2.96 (2.08–3.7)
Obese patients 36 3.60 (2.95–3.9)a
Non-IR patients 30 1.7 (0.82–2.2)
IR patients 43 1.9 (1.12–2.4)b
Data are medians (25th and 75th centiles-quartiles). asigniﬁcant diﬀerence
from lean patientsatP ≤ 0.05. bsigniﬁcantdiﬀerence from non-IR patients
at P ≤ 0.05.
covariants. Studiesassessing apelin-36andapelin-12 levelsin
patients with nonalcoholic fatty liver disease (NAFLD) indi-
cated that the elevation of this peptide did not persist after
adjustment for potential confounders and rather attributed
apelin elevation in these cases to obesity and IR that are
closely associated with NAFLD [27, 28].
In contrast to NAFLD models, the present study shows
that serum apelin level is elevated in patients with either
ﬁbrosis or cirrhosis due to HCV, with signiﬁcant diﬀerences
among the two groups being higher in the latter, even after
apelinadjustment.This isinlinewithpreviousinvestigations
demonstrating that patients with cirrhosis showed signiﬁ-
cant increase in apelin circulating levels [11, 29].
Moreover, recent emerging studies speculated that acti-
vated hepatic stellate cells (HSCs) represent a potential
source for apelin in liver [11] and that apelin could be an
important mediator of the proﬁbrogenic gene induction that
markedly stimulates collagen-I synthesis [10]. In addition,
apelin contributes to platelet-derived growth factor-induced
proliferation of HSC’s in vitro [12], all of which are known
to contribute largely to ﬁbrosis progression and extracellular
matrix deposition [30, 31]. In this setting, we also found
apelinserumleveltobesigniﬁcantly elevatedinpatientswith
ﬁbrosis. Thus, apelin emerges as a major contributor to the
ﬁbrogenic process(es) occurring in liver disease [10]a sw e l l
as playing role in disease progression.
On the other hand, this elevation in case of ASC
disappeared after apelin adjustment to cofounders, which
points to the interference of these cofactors in elevating
apelin levels and may result in the early upset of the system
in CHC patients.
Moreover, the current study demonstrated that this pep-
tide is closely associated to ascites and portal hypertension
complications. Tiani and his coworkers suggested that the
expression of endogenous apelin/APJ signaling is associatedMediators of Inﬂammation 5
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Figure 1: (a) Regression analysis showing correlation between
adjusted-apelin and HOMA.IR among CHC patients (n = 73). (b)
Regression analysis showing correlation between adjusted-apelin
and TNF-α among CHC patients (n = 73).
Table 5: Correlation coeﬃcients (r)o fd i ﬀerent parameters in pa-
tients with CHC (n = 73).
Parameters/groups
Adjusted-apelin (ng/mL)
ASC Fibrosis Cirrhosis
n 20 20 33
TNF-α (pg/mL) 0.26NS −0.212NS −0.488∗∗
HOMA-IR 0.665∗∗ 0.202NS 0.18NS
r = Spearman’s rank correlation coeﬃcients. ∗∗, ∗∗∗Correlation is signiﬁ-
cant at the 0.01, 0.001 level. NS: nonsigniﬁcant correlation.
with development of portal hypertension and contributes
to the formation of portosystemic collateral blood vessels
andsplanchnicneovascularizationinportalhypertensiverats
[26].
In the last few years, several data have accumulated sug-
gesting that obesity also plays role in development and pro-
gression of liver disease of well-deﬁned etiology [32]. Re-
cently, expression of both apelin and APJ has been described
in adipocytes [7] and is suggested to stimulate blood vessel
growth, due to its proangiogenic activity, thus leading to
increased growth of adipose tissue [33]. Coincidingwith that
line, our study also demonstrated that obese subjects with
CHC had signiﬁcant increased circulating apelin levels than
lean patients, regardless of the stage or grade of liver disease.
On the other hand, studiesalso demonstrated that apelin
expression was higher in animal models of obesity associated
with hyperinsulinemia [7], in addition to its role in adipoge-
nesis [33] and steatosis [8]; all of which contribute largely to
ﬁ br os ispr ogr es s ion ,a sw ella sh igh erdegr eeofin ﬂ a m m a tion
[32,34].Besides,virusCinfectionmayinduceIRbyblocking
intracellular signaling [35]. Further insight in our study
revealed that IR was signiﬁcantly higher among all groups
of CHC in comparison to the control group. Moreover,
signiﬁcant diﬀerence was also found between ASC and
cirrhotic groups, being higher in the latter. Moreover, when
comparing apelin levels in IR and non-IR groups, it was
signiﬁcantly higher in IR group. Additionally, there was sig-
niﬁcant positive correlation between IR and adjusted-apelin
in patients with CHC. This is in agreement with a previous
study conducted by Aktas et al., who depicted that apelin,
the novel adipokine, was associated with the components of
the metabolic syndrome (hyperlipidemia, obesity, and IR)
in NAFLD patients [27]. However, our correlation was quite
signiﬁcantinASCbutwasunexpectedlynonsigniﬁcantinthe
case of progressive stages of ﬁbrosis and cirrhosis, suggesting
that the upset of the apelin system in these stages may follow
au n i q u ed i ﬀerent pattern irrelevant to IR.
Moreover, previous investigations had pointed to TNF-α
as an inductor of apelin synthesis in adipocytes [36]. Hence,
we sought to investigate such correlation in our CHC popu-
lation. TNF-α was mostly elevated in cases of ASC, this was
in agreement with Zekri and his coworkers [37] but was op-
posite to what was reported by Goyal et al. [38]a n dT o y o d a
et al. [39]. This could be attributed to the diﬀerence in the
epitopes of the ELISA system used by the diﬀerent inves-
tigating groups or to the diﬀerence in genotypes where all
our patients were HCV genotype 4. Moreover, the striking
elevation of this proinﬂammatory cytokine in carriers may
reﬂect both insuﬃciencies of HCV elimination and/or a
failure to control the cytokine cascade [37].
In the current study, negative correlation was found
between TNF-α and adjusted-apelin in patients with CHC.
Further analysis of such correlation in CHC groups revealed
a positive correlation between TNF-α a n da p e l i ni nc a s e so f
ASC but was nonsigniﬁcant after adjustment for covariants,
emphasizing the role of covariants in the induction of apelin
in early stages of hepatitis. Interestingly, in case of, cirrhosis,
there was signiﬁcant negative correlation, suggesting that
apelin induction in CLD follows alternative signaling path-
ways. This is in agreement with Melgar-Lesmes and his co-
workers who pointed to the diminution of apelin expression
induced by TNF-α in HSC cultures and explained that it
could represent a homeostatic protective response toward
reducing the overactivated hepatic apelin system in patients
with advanced liver disease [10].
These ﬁndings point to thepossible roleof apelin in CLD
progression. Moreover, this provides a rationale to investi-
gate new drugs targeting the apelin/APJ signaling pathway
to reduce ﬁbrosis and to improve hemodynamics in those
patients.6 Mediators of Inﬂammation
5.Conclusion
Circulating serum apelin level varies in diﬀerent stages of
CHC, which in conjunction with IR and obesity, would con-
tribute to ﬁbrosis progression. Additionally, apelin is more
elevated in patients with ascites and portal hypertension and
may have role in the development of these complications.
Apelin, being recently added to the list of “adiposity signals,”
in this setting, apelin targeting could be of additional beneﬁt
in obese patients with concomitant CLD, for alleviating both
conditions and possibly resulting in better outcomes.
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